Disopyramide Phosphate(dye soe peer’ a mide)
Norpace, Norpace CRDNC, Rythmodan (CAN), Rythmodan-LA (CAN)DNC
PREGNANCY CATEGORY C
Drug Classes
Antiarrhythmic
Therapeutic Actions
Type 1a antiarrhythmic: Decreases rate of diastolic depolarization, decreases automaticity, decreases the rate of rise of the action potential, prolongs the refractory period of cardiac muscle cells.
Indications
Treatment of ventricular arrhythmias considered to be life-threatening
Unlabeled use: Treatment of paroxysmal supraventricular tachycardia
Contraindications and Cautions
Contraindicated with cardiogenic shock, allergy to disopyramide, cardiac conduction abnormalities (eg, Wolff-Parkinson-White syndrome, sick sinus syndrome, heart block, prolonged QT interval).
Use cautiously with heart failure, hypotension, cardiac myopathies, urinary retention, glaucoma, myasthenia gravis, renal or hepatic disease, potassium imbalance, pregnancy, lactation.
Available Forms
Capsules—100, 150 mg; CR capsulesDNC—100, 150 mg; ER tabletsDNC—150 mg (CAN)
Dosages
Evaluate patient carefully and monitor cardiac response closely to determine the correct dosage for each patient.
Dosages
Adults
400–800 mg/day PO given in divided doses every 6 hr or every 12 hr if using the CR products.
Rapid control of ventricular arrhythmias: 300 mg PO (immediate release). If no response within 6 hr, give 200 mg PO every 6 hr; may increase to 250–300 mg every 6 hr if no response in 48 hr.
Patients with cardiomyopathy: No loading dose, 100 mg PO every 6–8 hr (immediate release).
Pediatric patients
Give in equal, divided doses every 6 hr PO, adjusting the dose to the patient’s need.
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
